Early treatment efficacy of S-adenosylmethionine in patients with intrahepatic cholestasis: A systematic review  

作　　者：Mazen Noureddin Suntje Sander-Struckmeier JoséM Mato 

机构地区：[1]Division of Digestive and Liver Diseases,Comprehensive Transplant Center,Cedars-Sinai Medical Center,Los Angeles,CA 90048,United State [2]Gastroenterology/Hepatology,Abbott Laboratories GmbH,Hannover 30173,Germany [3]CIC bioGUNE,Basque Research and Technology Alliance(BRTA),CIBERehd,Derio 48160,Bizkaia,Spain

出　　处：《World Journal of Hepatology》2020年第2期46-63,共18页世界肝病学杂志（英文版）（电子版）

摘　　要：BACKGROUND S-adenosylmethionine(AdoMet)is a metabolically pleiotropic molecule used to treat intrahepatic cholestasis(IHC)and chronic liver diseases.While the efficacy of AdoMet has been demonstrated previously,it has not been systematically investigated within the early weeks of treatment.AIM To systematically review the early treatment efficacy of AdoMet in adult patients with IHC.METHODS Studies reporting the efficacy of intravenous,intramuscular,or oral forms of AdoMet within 8 wk of treatment initiation were considered;three randomized and six non-randomized studies were eligible for inclusion(PROSPERO registration number CRD42018090936).Of the three randomized studies,two were double-blind and placebo-controlled,and one was comparator-controlled with unclear blinding and a relatively high risk of bias.Mean serum levels of alanine aminotransferase(ALT),aspartate aminotransferase(AST),alkaline phosphatase(ALP),and gamma-glutamyl transferase(γGT)following AdoMet treatment vs placebo,comparator,or baseline were summarized to determine differences in liver enzymes.Changes in patient-reported clinical symptoms of cholestasis were also summarized.RESULTS Both placebo-controlled randomized studies reported significant reductions in serum ALT levels with AdoMet vs placebo within 2 wk.One of these also reported significant ALP reductions,and the other reported significant AST andγGT reductions within 2 wk.The comparator-controlled randomized study,which had a number of notable limitations,reported significant reductions in serum ALT and AST levels with AdoMet vs potassium magnesium aspartate within 4 wk,but not within2 wk.All of the non-randomized studies(4/4)that investigated ALT,AST,ALP and/orγGT reported significant reductions in at least two of these parameters within 2 wk.Of the five studies that evaluated fatigue,reductions were observed within 2 wk in one randomized and two nonrandomized studies.The remaining two non-randomized studies reported improvements in fatigue within 6 and 8 wk.Of the four studies rBACKGROUND S-adenosylmethionine(Ado Met) is a metabolically pleiotropic molecule used to treat intrahepatic cholestasis(IHC) and chronic liver diseases. While the efficacy of Ado Met has been demonstrated previously, it has not been systematically investigated within the early weeks of treatment.AIM To systematically review the early treatment efficacy of Ado Met in adult patients with IHC.METHODS Studies reporting the efficacy of intravenous, intramuscular, or oral forms of Ado Met within 8 wk of treatment initiation were considered; three randomized and six non-randomized studies were eligible for inclusion(PROSPERO registration number CRD42018090936). Of the three randomized studies, two were double-blind and placebo-controlled, and one was comparator-controlled with unclear blinding and a relatively high risk of bias. Mean serum levels of alanine aminotransferase(ALT), aspartate aminotransferase(AST), alkaline phosphatase(ALP), and gamma-glutamyl transferase(_γGT) following Ado Met treatment vs placebo, comparator, or baseline were summarized to determine differences in liver enzymes. Changes in patient-reported clinical symptoms of cholestasis were also summarized.RESULTS Both placebo-controlled randomized studies reported significant reductions in serum ALT levels with Ado Met vs placebo within 2 wk. One of these also reported significant ALP reductions, and the other reported significant AST and _γGT reductions within 2 wk. The comparator-controlled randomized study,which had a number of notable limitations, reported significant reductions in serum ALT and AST levels with Ado Met vs potassium magnesium aspartate within 4 wk, but not within2 wk. All of the non-randomized studies(4/4) that investigated ALT, AST, ALP and/or _γGT reported significant reductions in at least two of these parameters within 2 wk. Of the five studies that evaluated fatigue, reductions were observed within 2 wk in one randomized and two nonrandomized studies. The remaining two non-randomized studies reported improvements in fatig

关 键 词：S-ADENOSYLMETHIONINE Intrahepatic cholestasis Chronic liver disease Liver enzymes Symptoms of cholestasis 

分 类 号：R575[医药卫生—消化系统]